UA106221C2 - Method for treatment of hiv - Google Patents

Method for treatment of hiv

Info

Publication number
UA106221C2
UA106221C2 UAA201109904A UAA201109904A UA106221C2 UA 106221 C2 UA106221 C2 UA 106221C2 UA A201109904 A UAA201109904 A UA A201109904A UA A201109904 A UAA201109904 A UA A201109904A UA 106221 C2 UA106221 C2 UA 106221C2
Authority
UA
Ukraine
Prior art keywords
epitopes
polypeptide
hiv
antigen
administering
Prior art date
Application number
UAA201109904A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Сильвен Фльори
Морган Бомсель
Original Assignee
Майметикс Корпорейшн
Инсерм (Институт Натионал Де Ла Санте Эт Де Ла Речерч Медикел)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Майметикс Корпорейшн, Инсерм (Институт Натионал Де Ла Санте Эт Де Ла Речерч Медикел) filed Critical Майметикс Корпорейшн
Priority claimed from PCT/EP2010/051524 external-priority patent/WO2010089402A1/en
Publication of UA106221C2 publication Critical patent/UA106221C2/en

Links

Abstract

The present invention deals with a method for treatment of HIV, in particular a prophylactic vaccinal method, comprising at least: administering to a patient a first antigen comprising the broadly neutralizing epitopes of the Membrane Proximal Ectodomain Region (MPER) of gp41, and administering to the same patient a second antigen comprising a modified polypeptide comprising three contiguous segments N, L and C represented by the formula N-L-C and comprising: a N-helix region of gp41(N), a C-helix region of gp41(C), and a connecting loop comprising a synthetic linker (L) between the N and C-helices, the linker replacing amino acids 593-617 of gp41, the numbering scheme being based upon the prototypic isolate HIV-1 HxB2 Clade B strain, said polypeptide comprising the calveolin-1 neutralizing and 98.6 D epitopes, but not 2F5 and 4F10 epitopes, not the fusion peptide, the polypeptide having a minimal immunogenic cross-reactivity with human interleukin 2.
UAA201109904A 2009-02-06 2010-02-08 Method for treatment of hiv UA106221C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20221909P 2009-02-06 2009-02-06
PCT/EP2010/051524 WO2010089402A1 (en) 2009-02-06 2010-02-08 Splitting gp41

Publications (1)

Publication Number Publication Date
UA106221C2 true UA106221C2 (en) 2014-08-11

Family

ID=52682156

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201109904A UA106221C2 (en) 2009-02-06 2010-02-08 Method for treatment of hiv

Country Status (1)

Country Link
UA (1) UA106221C2 (en)

Similar Documents

Publication Publication Date Title
Beddows et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
US9822165B2 (en) Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external region
Grundner et al. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins
CN1913919B (en) HIV vaccines based on env of multiple clades of hiv
Krebs et al. Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA
Kang et al. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1
Qi et al. A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice
Wu et al. Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies
McGaughey et al. Progress towards the development of a HIV-1 gp41-directed vaccine
Chakrabarti et al. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate
US8790898B2 (en) Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
WO2012003234A3 (en) Env trimer immunogens
Moriya et al. Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies
WO2008005929A3 (en) Recombinant hiv-1 gp120 immunogen with three different v3 loops from viruses of different clades
Khattar et al. Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector
MX2011007745A (en) Splitting gp41.
Gonelli et al. Immunogenicity of HIV-1-based virus-like particles with increased incorporation and stability of membrane-bound Env
Shrivastava et al. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response
Zhang et al. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen
Lu et al. Polyvalent AIDS vaccines
Du et al. Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein
Carlos et al. Immunogenicity of a vaccine preparation representing the variable regions of the HIV type 1 envelope glycoprotein
UA106221C2 (en) Method for treatment of hiv
Lockey et al. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees
Huang et al. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses